Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 3/20 | 0.37 |
| ▸ | MMP9 | P14780 | 3/20 | 0.37 |
| ▸ | MMP8 | P22894 | 3/20 | 0.37 |
| ▸ | MMP13 | P45452 | 3/20 | 0.37 |
| ▸ | STAT3 | P40763 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | VDR | P11473 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | XBP1 | P17861 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16898488 | 1.00 | ALDH1A1 (0.42) | ALDH1A1CA12CA1CA9ABCG2 | |
| SCHEMBL18858985 | 1.00 | ALDH1A1 (0.42) | ALDH1A1CA12CA1CA9ABCG2 | |
| SCHEMBL27189795 | 1.00 | ALDH1A1 (0.42) | ALDH1A1CA12CA1CA9ABCG2 | |
| SCHEMBL13764444 | 1.00 | ALDH1A1 (0.42) | ALDH1A1CA12CA1CA9ABCG2 | |
| SCHEMBL16898408 | 1.00 | ALDH1A1 (0.42) | ALDH1A1CA12CA1CA9ABCG2 | |
| SCHEMBL14845475 | 1.00 | ALDH1A1 (0.42) | ALDH1A1CA12CA1CA9ABCG2 | |
| SCHEMBL31395440 | 1.00 | ALDH1A1 (0.42) | ALDH1A1CA12CA1CA9ABCG2 | |
| SCHEMBL16898333 | 1.00 | ALDH1A1 (0.42) | ALDH1A1CA12CA1CA9ABCG2 | |
| SCHEMBL13497897 | 1.00 | ALDH1A1 (0.42) | ALDH1A1CA12CA1CA9ABCG2 | |
| SCHEMBL31145779 | 0.96 | ALDH1A1 (0.39) | ALDH1A1CA12CA1CA9ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4729615-A1 | SIRNA TARGETING MMP7, SIRNA CONJUGATE AND MEDICAL USE THEREOF | Tuojie Biotech (Shanghai) Co., Ltd. (CN) | 2026-04-22 | — | — | EP | disclosed |
| US-20260043029-A1 | RNAi Agents for Inhibiting Expression of Thymic Stromal Lymphopoietin (TSLP), Compositions Thereof, and Methods of Use | ARROWHEAD PHARMACEUTICALS INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-20260014261-A1 | TARGETED PROTEIN MODIFICATION | WEATHERWAX BIOTECHNOLOGIES CORP (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4665355-A2 | RNAI AGENTS FOR INHIBITING EXPRESSION OF THYMIC STROMAL LYMPHOPOIETIN (TSLP), COMPOSITIONS THEREOF, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-4658788-A2 | OPTIMIZED RNAI AGENTS FOR INHIBITING EXPRESSION OF CORONAVIRUS (COV) VIRAL GENOMES, COMPOSITIONS THEREOF, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2025-12-10 | — | — | EP | disclosed |
| US-12486502-B2 | RNAi agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use | Arrowhead Pharmaceuticals, Inc. (US) | 2025-12-02 | — | — | US | disclosed |
| EP-4648782-A1 | RNAI AGENTS FOR INHIBITING INFLUENZA A VIRAL GENE EXPRESSION, COMPOSITIONS THEREOF, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2025-11-19 | — | — | EP | disclosed |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4613773-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
| EP-3886904-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| CN-113423427-A | IRAK degrading agents and uses thereof | 凯麦拉医疗公司 | 2021-09-21 | — | — | CN | disclosed |
| US-11117889-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-10874743-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| EP-3731869-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2020-11-04 | — | — | EP | disclosed |
| WO-2020113233-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-06-04 | — | — | WO | disclosed |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| WO-2015106292-A1 | BCR-ABL TYROSINE-KINASE LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2015-07-16 | — | — | WO | disclosed |
| WO-2015106292-A1 | BCR-ABL TYROSINE-KINASE LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2015-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874743-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885CA12 4583/4885CA1 4622/4885 |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885CA12 4583/4885CA1 4622/4885 |
| US-11117889-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885CA12 4583/4885CA1 4622/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885CA12 4583/4885CA1 4622/4885 |
| US-20260014261-A1 | TARGETED PROTEIN MODIFICATION | MDM2, TP53, VHL | ALDH1A1 4015/4885CA12 3614/4885CA1 3879/4885 |
| US-12486502-B2 | RNAi agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use | AGER, ASGR1, TLR3 | ALDH1A1 1945/4885CA12 4626/4885CA1 4806/4885 |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885CA12 4583/4885CA1 4622/4885 |
| US-20260043029-A1 | RNAi Agents for Inhibiting Expression of Thymic Stromal Lymphopoietin (TSLP), Compositions Thereof, and Methods of Use | TSLP, RBM26, TEK | ALDH1A1 4550/4885CA12 4503/4885CA1 4737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.